News

Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple…
Read More...

Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has…
Read More...

Sanofi restructures its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. Under the amended and restated license and collaboration agreement, Regeneron will obtain…
Read More...

Biogen Inc. and Samsung Bioepis Co., Ltd. announced that BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab)i has been launched in the United States. Healthcare…
Read More...

Moderna, Inc. announced an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Moderna COVID-19 vaccine booster product…
Read More...

Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40…
Read More...

Theolytics is a biotechnology company harnessing viruses to combat disease. The company has been awarded a Biomedical catalyst grant by Innovate UK to progress a novel therapy for…
Read More...

Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle,…
Read More...

Cocrystal Pharma, Inc. announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to…
Read More...

Amneal Pharmaceuticals, Inc. announced the commercial launch of LYVISPAH, a baclofen oral granules (5, 10 and 20 mg) specialty product approved by the U.S. Food and Drug Administration…
Read More...

Astellas Pharma Inc. and GO Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and GO have entered into a strategic research…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under two months old with spinal muscular…
Read More...

GSK plc announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston,…
Read More...

BONE THERAPEUTICS announces that it has signed the definitive subscription agreement for a maximum EUR 5 million convertible bonds (CBs) facility arranged by ABO Securities, through its…
Read More...

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda announced to transfer the marketing authorization in Japan for Moderna’s…
Read More...

NRG Therapeutics Ltd an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC)…
Read More...

Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or…
Read More...

Jubilant Pharmova Limited has announced that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier…
Read More...

Sirnaomics Ltd. a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the launch of a Phase I clinical trial of the Company's siRNA…
Read More...

Evotec SE announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price…
Read More...